Items where authors include "Cacciapaglia, F."

Article

De Lorenzis, E., Natalello, G., Pellegrino, G. et al. (29 more authors) (2024) Long-term retention rate, adverse event temporal patterns and rescue treatment strategies of mycophenolate mofetil in systemic sclerosis: insights from real-life. Rheumatology. keae532. ISSN 1462-0324

Deibel, E. orcid.org/0000-0003-4652-9826, Carreira, P.E., Vonk, M. orcid.org/0000-0002-2266-9907 et al. (61 more authors) (2024) Does the Impact of COVID-19 on Patients With Systemic Sclerosis Change Over Time? Arthritis Care & Research, 76 (1). pp. 88-97. ISSN 2151-464X

Kuster, S., Jordan, S., Elhai, M. et al. (104 more authors) (2022) Effectiveness and safety of tocilizumab in patients with systemic sclerosis: a propensity score matched controlled observational study of the EUSTAR cohort. RMD Open, 8 (2). e002477. ISSN 2056-5933

Conference or Workshop Item

Verardi, L., De Lorenzis, E., Pellegrino, G. et al. (19 more authors) (2023) POS1324 mycophenolate mofetil use in clinical practice in a multicentric cohort of scleroderma patients: persistence on therapy and long-term adverse events. In: EULAR 2023 European Congress of Rheumatology, 31 May - 03 Jun 2023, Milan, Italy.

Proceedings Paper

Moschetti, L., Rovaris, S., Bonomi, F. et al. (35 more authors) (2025) OP0217 THE CLINICAL PHENOTYPE OF ANTI-Th/To+ PATIENTS IN SYSTEMIC SCLEROSIS: A CASE-CONTROL STUDY WITHIN THE EUROPEAN SCLERODERMA TRIALS AND RESEARCH (EUSTAR) COHORT. In: Annals of the Rheumatic Diseases. EULAR 2025: European Congress of Rheumatology, 11-14 Jun 2025, Barcelona, Spain. BMJ Publishing Group , pp. 181-182.

Moschetti, L., Pedretti, E., Bonomi, F. et al. (27 more authors) (2024) The Clinical Phenotype of Anti-Th/To plus Patients in Systemic Sclerosis: A Case-control Study Within the European Scleroderma Trials and Research (EUSTAR) Cohort. In: Arthritis & Rheumatology. ACR Convergence 2024, 14-19 Nov 2024, Washington D.C., USA. Wiley , pp. 4955-4958.